title: Public health. A sound rationale needed for phase III HIV-1 vaccine trials.
authors.affiliation: Scripps Research Institute, La Jolla, California, USA.
authors.forename: Dennis R
authors.initials: DR
authors.lastname: Burton
authors.forename: Ronald C
authors.initials: RC
authors.lastname: Desrosiers
authors.forename: Robert W
authors.initials: RW
authors.lastname: Doms
authors.forename: Mark B
authors.initials: MB
authors.lastname: Feinberg
authors.forename: Robert C
authors.initials: RC
authors.lastname: Gallo
authors.forename: Beatrice
authors.initials: B
authors.lastname: Hahn
authors.forename: James A
authors.initials: JA
authors.lastname: Hoxie
authors.forename: Eric
authors.initials: E
authors.lastname: Hunter
authors.forename: Bette
authors.initials: B
authors.lastname: Korber
authors.forename: Alan
authors.initials: A
authors.lastname: Landay
authors.forename: Michael M
authors.initials: MM
authors.lastname: Lederman
authors.forename: Judy
authors.initials: J
authors.lastname: Lieberman
authors.forename: Joseph M
authors.initials: JM
authors.lastname: McCune
authors.forename: John P
authors.initials: JP
authors.lastname: Moore
authors.forename: Neal
authors.initials: N
authors.lastname: Nathanson
authors.forename: Louis
authors.initials: L
authors.lastname: Picker
authors.forename: Douglas
authors.initials: D
authors.lastname: Richman
authors.forename: Charles
authors.initials: C
authors.lastname: Rinaldo
authors.forename: Mario
authors.initials: M
authors.lastname: Stevenson
authors.forename: David I
authors.initials: DI
authors.lastname: Watkins
authors.forename: Steven M
authors.initials: SM
authors.lastname: Wolinsky
authors.forename: Jerome A
authors.initials: JA
authors.lastname: Zack
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D017326:Clinical Trials, Phase III as Topic / Q000191:economics; D003365:Costs and Cost Analysis; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D013785:Thailand; D014481:United States; D014614:Vaccines, Synthetic / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D015699:HIV Envelope Protein gp120; D014614:Vaccines, Synthetic